Drug intelligence / Profile preview

NQ2050

Development stage: Preclinical
Lead developer: Novaliq
Modality: Small Molecules
Administration: Ophthalmic

Overview

NQ2050 is a preclinical-stage small molecule drug candidate developed by Novaliq for the treatment of diabetic retinopathy. It is formulated using Novaliq's proprietary EyeSol® technology, a water-free, perfluorohexyloctane-based platform designed to enable the topical delivery of active ingredients to the posterior segment of the eye. This approach aims to provide a non-invasive eye drop alternative to the standard-of-care intravitreal injections for retinal diseases. As of the current pipeline status, the specific molecular target and mechanism of action for NQ2050 remain undisclosed.

Beyond the preview

Go deeper on NQ2050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NQ2050.

Explore the full profile